Cover Image
市場調查報告書

非肌肉侵襲性膀胱癌 (NMIBC) (表淺性膀胱癌) :開發中產品分析

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251532
出版日期 內容資訊 英文 182 Pages
訂單完成後即時交付
價格
Back to Top
非肌肉侵襲性膀胱癌 (NMIBC) (表淺性膀胱癌) :開發中產品分析 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 182 Pages
簡介

非肌肉侵襲性膀胱癌代表症狀有血尿、頻尿、骨盆疼痛等。該疾病的致病要素有高齡化、吸煙等。治療法有外科手術、化療、放射線療法等。

本報告提供非肌肉侵襲性膀胱癌 (NMIBC) (表淺性膀胱癌) 的治療藥開發情形相關調查,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

非肌肉侵襲性膀胱癌 (NMIBC) (表淺性膀胱癌)的概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

非肌肉侵襲性膀胱癌 (NMIBC) (表淺性膀胱癌) :企業開發中的治療藥

非肌肉侵襲性膀胱癌 (NMIBC) (表淺性膀胱癌) :大學/機關研究中的治療藥

非肌肉侵襲性膀胱癌 (NMIBC) (表淺性膀胱癌) :開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

非肌肉侵襲性膀胱癌 (NMIBC) (表淺性膀胱癌) :企業開發中的產品

非肌肉侵襲性膀胱癌 (NMIBC) (表淺性膀胱癌) :大學/機關研究中的產品

非肌肉侵襲性膀胱癌 (NMIBC) (表淺性膀胱癌)的治療藥的開發企業

  • Altor BioScience Corporation
  • APIM Therapeutics AS
  • Astellas Pharma Inc.
  • Bavarian Nordic A/S
  • BioCancell Ltd
  • Celgene Corporation
  • Cold Genesys, Inc.
  • Heat Biologics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Taris Biomedical LLC
  • Telesta Therapeutics Inc.
  • UroGen Pharmaceuticals, Ltd.
  • Vakzine Projekt Management GmbH
  • Viralytics Ltd.
  • Viventia Bio Inc.

非肌肉侵襲性膀胱癌 (NMIBC) (表淺性膀胱癌) :治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

非肌肉侵襲性膀胱癌 (NMIBC) (表淺性膀胱癌) :最近的開發平台趨勢

非肌肉侵襲性膀胱癌 (NMIBC) (表淺性膀胱癌) :暫停中的計劃

非肌肉侵襲性膀胱癌 (NMIBC) (表淺性膀胱癌) :中止開發的產品

非肌肉侵襲性膀胱癌 (NMIBC) (表淺性膀胱癌) :產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8501IDB

Summary

Global Markets Direct's, 'Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2016', provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
  • The report reviews pipeline therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) therapeutics and enlists all their major and minor projects
  • The report assesses Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview
  • Therapeutics Development
    • Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Overview
    • Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Development by Companies
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Investigation by Universities/Institutes
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Development by Companies
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Investigation by Universities/Institutes
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Companies Involved in Therapeutics Development
    • Altor BioScience Corporation
    • APIM Therapeutics AS
    • Astellas Pharma Inc.
    • Bavarian Nordic A/S
    • BioCancell Ltd
    • Celgene Corporation
    • Cold Genesys, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Heat Biologics, Inc.
    • Merck & Co., Inc.
    • Spectrum Pharmaceuticals, Inc.
    • Taris Biomedical LLC
    • UroGen Pharmaceuticals, Ltd.
    • Vakzine Projekt Management GmbH
    • Vaxiion Therapeutics, Inc.
    • Viralytics Ltd.
    • Viventia Bio Inc.
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALT-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALT-803 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • apaziquone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • atezolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BC-819 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Superficial Bladder Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cavatak - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-0070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CV-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DAB-389EGF - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • docetaxel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for NMIBC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • erlotinib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gemcitabine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imiquimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lenalidomide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mitomycin SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize EGFR for Superficial Bladder Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nitroxoline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-MAPA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • paclitaxel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rAd-IFN - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sirolimus albumin-bound - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAX-014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VB-4845 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vesigenurtucel-L - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPM-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Dormant Projects
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Discontinued Products
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 10, 2016: TARIS Biomedical Launches Second Phase 1b Clinical Trial of TAR-200 (GemRIS) in Patients with Bladder Cancer
      • May 06, 2016: Spectrum Pharmaceuticals Highlights an Oral Presentation on Apaziquone at the 2016 Annual Meeting of the American Urological Association Education and Research (AUA) in San Diego, California, May 6-10, 2016
      • May 05, 2016: UroGen Pharma Announces Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association's 2016 Annual Meeting
      • Apr 07, 2016: Heat Biologics Announces Cost-Saving Measures and Focused Corporate Strategy to Achieve Important Clinical Milestone
      • Feb 25, 2016: Heat Biologics Provides Update on Its HS-410 Phase II Monotherapy Bladder Cancer Trial Arm
      • Feb 19, 2016: Spectrum Pharmaceuticals Announces FDA Acceptance of NDA Filing for EOquin (apaziquone for intravesical instillation)
      • Feb 10, 2016: FDA Lifts Heat Biologics Partial Clinical Hold
      • Feb 03, 2016: Heat Biologics Reports Update on Its HS-410 Phase 2 Bladder Cancer Trial
      • Jan 26, 2016: Heat Biologics CSO to Present Interim Results From the Monotherapy Arm in Its Ongoing HS-410 Phase 2 Bladder Cancer Trial at the Phacilitate Immunotherapy World Conference
      • Jan 13, 2016: UroGen Pharma Expands Uro-Oncology Clinical Pipeline with Addition of TLR-7 Agonist Phase 2 Asset
      • Nov 06, 2015: Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results at the Society for Immunotherapy of Cancer Annual Meeting
      • Nov 03, 2015: Results of Heat Biologics' HS-410 Phase 1 Safety Trial in Non-Muscle Invasive Bladder Cancer to be Presented at SITC Annual Meeting
      • Oct 26, 2015: Spectrum Pharmaceuticals Initiates Apaziquone Pivotal Trial for the Treatment of Non-Muscle Invasive Bladder Cancer Following SPA Agreement
      • Aug 17, 2015: Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Upcoming Apaziquone Phase 3 Trial in Patients with Non-Muscle Invasive Bladder Cancer
      • Jul 02, 2015: Viventia Begins Recruitment of Clinical Centers as it Prepares to Initiate Phase 3 Clinical Trial of Vicinium(TM) for the Treatment of Non-Muscle-Invasive Bladder Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H2 2016
  • Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Altor BioScience Corporation, H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by APIM Therapeutics AS, H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Astellas Pharma Inc., H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Bavarian Nordic A/S, H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by BioCancell Ltd, H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Celgene Corporation, H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Cold Genesys, Inc., H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Heat Biologics, Inc., H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Merck & Co., Inc., H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Taris Biomedical LLC, H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by UroGen Pharmaceuticals, Ltd., H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Vakzine Projekt Management GmbH, H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Vaxiion Therapeutics, Inc., H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Viralytics Ltd., H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Viventia Bio Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Dormant Projects, H2 2016
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H2 2016
  • Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top